Terns Pharmaceuticals $86 million stock offering
The stock is listed on the Nasdaq Global Select Market
Davis Polk advised the representatives of the several underwriters in connection with the $86 million public offering of SEC-registered shares of common stock by Terns Pharmaceuticals, Inc., which includes the exercise in full by the underwriters of their option to purchase additional shares. The common stock is listed on the Nasdaq Global Select Market under the symbol “TERN.”
Headquartered in Foster City, California, Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH).
The Davis Polk corporate team included partner Yasin Keshvargar and associates Michael Schuster and Courtney Clark. Partner David R. Bauer and associate Alison T. Chin provided intellectual property advice. Partner Corey M. Goodman and associate Kendra Simpson provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.